Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.57 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.57 |
| ▸ | CCR2 | P41597 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 6/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16353290 | 0.84 | AKR1C3 (0.78) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL20195005 | 0.84 | AKR1C3 (0.54) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL16061925 | 0.82 | AKR1C3 (0.49) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL30223686 | 0.81 | LMNA (0.50) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL19469640 | 0.81 | AKR1C3 (0.51) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL20365030 | 0.81 | AKR1C3 (0.48) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL1465569 | 0.81 | LMNA (0.50) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL10110050 | 0.81 | CCR2 (0.42) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL31045572 | 0.80 | APP (0.50) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL12050450 | 0.80 | AKR1C3 (0.57) | AKR1C1AKR1C3AKR1C2AKR1B10AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017051355-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017017607-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | WO | disclosed |
| US-9351962-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150126566-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2015-05-07 | — | — | US | disclosed |
| US-8962856-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140121381-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| US-8586615-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120010257-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-20080161371-A1 | Modulators of cystic fibrosis transmembrane conductance regulator | FIRST-CITIZENS BANK & TRUST COMPANY | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010257-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | AKR1C1 2566/4885AKR1C3 2201/4885AKR1C2 2180/4885 |
| US-20150126566-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | AKR1C1 2566/4885AKR1C3 2201/4885AKR1C2 2180/4885 |
| US-20140121381-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | AKR1C1 2566/4885AKR1C3 2201/4885AKR1C2 2180/4885 |
| US-20080161371-A1 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | AKR1C1 2566/4885AKR1C3 2201/4885AKR1C2 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.